Saturna Capital Corp Anavex Life Sciences Corp. Transaction History

Saturna Capital Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$7.66 - $9.5 $41,440 - $51,395	-5,410 Reduced 30.14%	12,540 $101,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $47,008 - $66,387	5,650 Added 45.93%	17,950 $153,000
Q1 2022 May 10, 2022	SELL	$9.74 - $17.69 $14,610 - $26,535	-1,500 Reduced 10.87%	12,300 $151,000
Q4 2021 Feb 09, 2022	BUY	$16.88 - $23.31 $3,376 - $4,662	200 Added 1.47%	13,800 $239,000
Q3 2021 Nov 08, 2021	BUY	$16.82 - $25.75 $8,410 - $12,875	500 Added 3.82%	13,600 $244,000
Q1 2021 May 14, 2021	BUY	$5.17 - $16.13 $67,727 - $211,303	13,100 New	13,100 $196,000

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $837M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Saturna Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Saturna Capital Corp with notifications on news.